News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
A Silenced Drug Study Creates An Uproar
March 27, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
The Washington Post -- The study would come to be called "cursed," but it started out just as Study 15.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Legal
MORE ON THIS TOPIC
Immunology and inflammation
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
February 10, 2026
·
1 min read
·
Dan Samorodnitsky
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
February 10, 2026
·
1 min read
·
Tristan Manalac
Insights
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
February 10, 2026
·
3 min read
·
Jennifer Smith-Parker
GLP-1
Novo Sues Hims & Hers Over Compounded Version of Oral Wegovy Pill
February 9, 2026
·
2 min read
·
Tristan Manalac